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limited to the lower parts of the epidermis where mild cytolo-
gical atypia is also seen. At the sides of the lesions inward
turning of the rete pegs is seen but there are no other findings
supportive of human papillomavirus infection. These particular
histological findings reflect the unusual clinical appearance of
these rather punctate keratotic lesions which do not fit into
the ordinary categories of solar keratoses or Bowen’s disease
seen on sun-exposed sites. Sunbed-related NMSC has been
reported but no reports have described the distinct appearance
and histology of these dysplastic lesions which could be syn-
onymous with sunbed use.
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SIR, The phototherapy-based treatment of psoriasis has been
greatly updated during the last decade. Among the newly
introduced devices, the 308-nm excimer laser1 has proved to
be effective in terms of rapidity of action and stability of
remissions.2,3 For about 3 years4 we have been using a 308-
nm XeCl monochromatic excimer light (MEL) (Excilite; Deka
Mela, Florence, Italy), able to generate 308-nm ultraviolet
(UV) B radiation, to produce a power density of 50 mW
cm)2 at a distance of 15 cm from source (decreasing to about
40 mW cm)2 at the periphery of the spot), and to have a
maximum irradiating area of 504 cm2 (36 · 14 cm).
Following the experience of Asawanonda et al.,5 we started
a new protocol based on multiples of the minimal erythema
dose (MED). Before treatment, all patients were phototested to
determine the MED of 308-nm UVB by exposing a small area
of uninvolved skin on the buttocks to a geometric dose range
between 150 and 500 mJ cm)2 (3–10 s). Sixty-nine patients
(44 men and 25 women) aged between 18 and 77 years,
with Fitzpatrick skin type I-IV, affected by both localized
(< 30% of total skin) and diffuse psoriasis vulgaris (> 30% of
total skin), were enrolled in this pilot study. Patients were
required to discontinue any topical treatment for 4 weeks, and
any phototherapy-based or systemic treatment for at least
3 months before enrolment. The psoriasis severity was evalu-
ated according to the Psoriasis Area and Severity Index (PASI
12–36). The dose at the first application varied from 2 to 4
MED, depending on the skin area to be treated and the fea-
tures (thickness, scaling and erythema) of the psoriatic lesion
(Table 1). Subsequent doses were increased by 150–500 mJ
cm)2 (3–10 s) during the following sessions (one every 7–
14 days), inversely depending on the erythema grading rela-
ted to the preceding application (the less erythema, the higher
increase). The lamp was always located at a distance of 15 cm
from the skin area to be treated. Both patients and operators
always wore protective goggles. Unaffected skin was always
protected with white paper towels or a total-block sunscreen
cream. No additional treatments, except an emollient cream
under occlusive dressing, were used by the patients during the
study period. No mineral oil, usually used in excimer laser
treatment, was applied in our protocol. Clinical evaluation was
performed once monthly during and after the treatment per-
iod up to a maximum follow-up of 13 months.
Complete remission was defined as 76–100% improvement
in PASI, partial remission as 51–75% improvement, minimal
response as 26–50% improvement and no response as 0–25%
improvement. Thirty of the 44 patients with localized psoriasis
Table 1 Initial light dose at different cutaneous areas
2 MED Lesions of lower limbs in patients with vascular
problems
2Æ5 MED Lesions at areas such as lower limbs, buttocks,
abdomen, breastbone area, extensor side of upper
limbs, face and scalp (with shaved hair)
3 MED Lesions of back and of dorsal side of arms and
hands
4 MED Lesions of elbows and knees
MED, minimal erythema dose.
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(Fig. 1) achieved complete remission (68%), 10 experienced
partial remission (23%), three showed a minimal response
(7%) and only one showed no response (2%); eight of the 25
patients with diffuse psoriasis achieved complete remission
(32%), 12 obtained partial remission (48%), three showed a
minimal response (12%) and two showed no response (8%).
In the localized psoriasis group, the number of sessions varied
from one to eight (mean 5Æ2, median 5Æ5), and remissions
lasted from 2 to 13 months (mean 4Æ2, median 4Æ5). In the
diffuse psoriasis group, the number of sessions varied from
two to 10 (mean 5Æ8, median 6), and remissions lasted from
1 to 5 months (mean 3Æ5, median 3Æ5). The most common
side-effects were minimal erythema and itching, with mild
and transient hyperpigmentation. These were recorded in all
patients, but were well tolerated (no drop-outs). Only three
lesions showed blisters after the first or second session.
Although the treatment of those lesions was stopped, remis-
sion was quickly achieved and lasted up to 1 year.
When compared with traditional phototherapy, MEL can
selectively treat single psoriatic lesions, thus sparing clinically
unaffected skin, and can achieve clinical remission very
quickly with one treatment every 7–14 days. Its major advan-
tages over the 308-nm excimer laser devices are both its lower
cost (about 65 000 vs. more than 80 000 euros) and its abil-
ity to give uniform irradiation of a 50-times wider area
(504 cm2) in a single exposure. Data in the literature indicate
that MEL may be an effective alternative to traditional photo-
therapy.6,7 Our preliminary results suggest that MEL photo-
therapy may prove to be very useful,8–10 especially for
localized psoriasis. The best protocol in terms of ratio between
risks (burns) and benefits (rapidity and stability of remission)
remains to be identified.
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Fig 1. Psoriasis inversa of the axilla (a) before treatment and (b)
4 months after last monochromatic excimer light treatment (two
treatments, 0.6 and 0.75 mW cm)2).
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